Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial

BACKGROUND: Masitinib is an oral tyrosine kinase inhibitor that selectively targets mast cell activity and platelet-derived growth factor receptor (PDGFR) signaling, both of which are implicated in various mechanisms of asthma pathogenesis. OBJECTIVE: Assessment of masitinib as an add-on to standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidescu, Lavinia, Ursol, Grigoriy, Korzh, Oleksii, Deshmukh, Vikranth, Kuryk, Lesia, Nortje, Monja-Marie, Godlevska, Olga, Devouassoux, Gilles, Khodosh, Eduard, Israel, Elliot, Moussy, Alain, Mansfield, Colin D, Hermine, Olivier, Chanez, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188333/
https://www.ncbi.nlm.nih.gov/pubmed/35698580
http://dx.doi.org/10.2147/JAA.S337284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188333/
https://www.ncbi.nlm.nih.gov/pubmed/35698580
http://dx.doi.org/10.2147/JAA.S337284

Ejemplares similares